Printer Friendly

Emergency contraceptive backed.

An FDA advisory panel unanimously agreed that the selective progesterone receptor modulator ulipristal acetate is an effective emergency contraceptive with an acceptable safety profile, when used within 5 days of unprotected intercourse or a known or suspected contraceptive failure.

The FDA's Reproductive Health Drugs Advisory Committee voted 11-0 that the manufacturer, HRA Pharma, had provided enough information to conclude that micronized ulipristal reduces the likelihood of pregnancy when taken within 120 hours after unprotected intercourse or a known or suspected contraceptive failure.

If approved by the FDA, the company plans to market it as a prescription-only product under the trade name ella. Currently, the levonorgestrel-based agent marketed as Plan B or Next Choice is the only emergency contraceptive available in the United States.

The most common side effects reported were headache, nausea, dysmenorrhea, and abdominal pain, according to the company.

COPYRIGHT 2010 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:NEWS FROM THE FDA
Publication:Internal Medicine News
Article Type:Brief article
Geographic Code:1USA
Date:Jul 1, 2010
Previous Article:Warning issued on fake 'Tamiflu'.
Next Article:Panel likes novel MS drug.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters